Cargando…
The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
BACKGROUND: Adalimumab is an anti‐tumour necrosis factor administered for the management of severe psoriasis. Previously limited to Humira, new biosimilar medications have now emerged including Amgevita. To date, there have been no comparison studies of adalimumab biosimilar use on different types o...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060077/ https://www.ncbi.nlm.nih.gov/pubmed/35663775 http://dx.doi.org/10.1002/ski2.60 |